Marker Therapeutics, Inc. (MRKR) · Oct 19, 2026 · Other events

Marker Therapeutics wins $2.6M FDA grant, delays trial to 2027

$2.6M FDA grant — $2.6M non-dilutive award; trial now targeted for Q1 2027 versus H1/Q2 2026

Marker Therapeutics won a $2.6M FDA grant for MT-601, adding non-dilutive funding but pushing its pancreatic cancer trial target to Q1 2027.

Marker is a clinical-stage cell-therapy company trying to move MT-601 from encouraging Baylor-led pancreatic-cancer data and its lymphoma program into a company-sponsored pancreatic Phase 1. Its June 30, 2026 filing showed $11.9 million in cash, equivalents, restricted cash, and government securities, so non-dilutive funding is strategically useful even before the program produces clinical data.

The grant is a real funding win, not just promotional validation. The FDA awarded Marker $2.6 million to support the MT-601 pancreatic-cancer Phase 1 study. Because the award is non-dilutive, it supports execution without requiring a new equity raise for this portion of the program. The selectivity helps the signal: six projects were chosen from 66 fiscal-year 2026 applications. 〔0〕

Filing figureWhat it means
$2.6 millionFDA grant supporting the MT-601 pancreatic-cancer Phase 1 study
6 of 66 applicationsSelectivity of the FDA grant process
84.6% disease-control ratePrior Baylor-led study result cited by Marker
7.5 monthsPrior median duration of response
14.1 monthsPrior median overall survival

The timing is the offsetting negative. Marker previously expected to start its company-sponsored pancreatic program in the first half of 2026, with later company materials narrowing that expectation to the second quarter; this filing now points to the first quarter of 2027. The grant therefore improves funding certainty while confirming that the program is moving later than the standing plan. 〔1〕

The clinical case is still preliminary, not newly proven by this filing. The 84.6% disease-control rate, 7.5-month response duration, and 14.1-month overall survival come from an earlier Baylor study, while Marker’s company-sponsored trial will change the design with broader antigen targeting, higher doses, and lymphodepletion. 〔2〕 The FDA award supports testing that hypothesis; it does not establish that the redesigned MT-601 regimen will reproduce or improve those results.

Bottom line: This is a meaningful financing and credibility boost for Marker’s pancreatic-cancer strategy, but it does not accelerate the program. The key change is better-funded execution against a trial now expected in Q1 2027, later than investors had previously been led to expect.

What to watch next

Pancreatic cancer Phase 1 initiation, Q1 2027

Original filing on SEC EDGAR

More Marker Therapeutics, Inc. news

Marker Therapeutics wins $2.6M FDA grant, delays trial to 2027 | MRKR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.